Matching-adjusted indirect comparison of selpercatinib and pralsetinib in RET fusion-positive non-small cell lung cancer

被引：0

作者：

Hochmair, Maximilian ^{[1
]}

Kiiskinen, Urpo ^{[2
,3
]}

D'yachkova, Yulia ^{[4
]}

Puri, Tarun ^{[5
]}

Wang, Xuwen ^{[6
]}

Wolowacz, Sorrel ^{[7
]}

Vickers, Adrian ^{[7
]}

Nadal, Ernest ^{[8
,9
]}

机构：

[1] Klin Floridsdorf, Karl Landsteiner Inst Lung Res & Pulm Oncol, Dept Resp & Crit Care Med, Vienna, Austria

[2] Eli Lilly & Co, Indianapolis, IN USA

[3] Eli Lilly & Co, Int Value & Access, Helsinki, Finland

[4] Eli Lilly & Co, Stat, Vienna, Austria

[5] Eli Lilly & Co, Thorac Oncol Global Med Affairs, Gurgaon, Haryana, India

[6] Eli Lilly & Co, Real World Adv Anal, Indianapolis, IN USA

[7] RTI Hlth Solut, Hlth Econ, Manchester, England

[8] Inst Catala Oncol ICO, Dept Med Oncol, Avda Granvia De Lhospitalet, Lhospitalet de Llobregat 08908, Barcelona, Spain

[9] Bellvitge Biomed Res Inst IDIBELL, Oncobell Program, Preclin & Expt Res Thorac Tumors PReTT Grp, Lhospitalet de Llobregat, Barcelona, Spain

来源：

FUTURE ONCOLOGY | 2025年 / 21卷 / 15期

关键词：

NSCLC; matching-adjusted indirect comparison; RET inhibitor; selpercatinib; pralsetinib; TYROSINE KINASE INHIBITOR; PREVIOUSLY TREATED PATIENTS; 2ND-LINE TREATMENT; NSCLC PATIENTS; RETROSPECTIVE ANALYSIS; PREDICTIVE FACTORS; PROGNOSTIC-FACTORS; TREATMENT PATTERNS; CLINICAL-OUTCOMES; PLATINUM-DOUBLET;

D O I：

10.1080/14796694.2025.2508132

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

AimsSelpercatinib and pralsetinib are approved for RET-rearranged non - small cell lung cancer.Materials & methodsEfficacy and safety were compared using matching-adjusted indirect comparison.ResultsMedian progression-free survival (PFS) was 22.1 and 13.3 months for selpercatinib and pralsetinib, respectively (HR = 0.67; 95% CI, 0.53-0.85). Objective response rate was 64.5% and 65.8%, and disease control rate was 92.1% and 90.4%, respectively. Median overall survival was not reached for selpercatinib and 43.9 months for pralsetinib (HR = 0.81; 95% CI, 0.60-1.09). Grade >= 3 treatment-related adverse events (TRAEs) were reported in 39.3% and 62.6% of patients, with discontinuations due to TRAEs in 3.6% and 10.0% of patients, respectively.ConclusionOutcomes were similar; however, PFS was significantly prolonged with selpercatinib, with fewer grade >= 3 TRAEs.

引用

页码：1867 / 1878

页数：12

共 97 条

[1] Clinical Outcomes and Prognostic Factors Associated with the Response to Erlotinib in Non-Small-Cell Lung Cancer Patients with Unknown EGFR Mutational Status [J].

Aydiner, Adnan ;

Yildiz, Ibrahim ;

Seyidova, Avesta .

ASIAN PACIFIC JOURNAL OF CANCER PREVENTION, 2013, 14 (05) :3255-3261

[2]

Bacha Saoussen, 2017, Tunis Med, V95, P772

[3]

Besse B, 2022, ANN ONCOL, V33, pS1083

[4]

Besse B, 2021, J THORAC ONCOL, V16, pS684

[5] FDA Approval Summary: Selpercatinib for the Treatment of Lung and Thyroid Cancers with RET Gene Mutations or Fusions [J].

Bradford, Diana ;

Larkins, Erin ;

Mushti, Sirisha L. ;

Rodriguez, Lisa ;

Skinner, Amy M. ;

Helms, Whitney S. ;

Price, Lauren S. L. ;

Zirkelbach, Jeanne Fourie ;

Li, Yangbing ;

Liu, Jiang ;

Charlab, Rosane ;

Turcu, Francisca Reyes ;

Liang, Dun ;

Ghosh, Soma ;

Roscoe, Donna ;

Philip, Reena ;

Zack-Taylor, Autumn ;

Tang, Shenghui ;

Kluetz, Paul G. ;

Beaver, Julia A. ;

Pazdur, Richard ;

Theoret, Marc R. ;

Singh, Harpreet .

CLINICAL CANCER RESEARCH, 2021, 27 (08) :2130-2135

[6] Simulating Survival Data Using the simsurv R Package [J].

Brilleman, Samuel L. ;

Wolfe, Rory ;

Moreno-Betancur, Margarita ;

Crowther, Michael J. .

JOURNAL OF STATISTICAL SOFTWARE, 2021, 97 (03) :1-27

[7] Retrospective Assessment of a Serum Proteomic Test in a Phase III Study Comparing Erlotinib plus Placebo with Erlotinib plus Tivantinib (MARQUEE) in Previously Treated Patients with Advanced Non-Small Cell Lung Cancer [J].

Buttigliero, Consuelo ;

Shepherd, Frances A. ;

Barlesi, Fabrice ;

Schwartz, Brian ;

Orlov, Sergey ;

Favaretto, Adolfo G. ;

Santoro, Armando ;

Hirsh, Vera ;

Ramlau, Rodryg ;

Blackler, Adele R. ;

Roder, Joanna ;

Spigel, David ;

Novello, Silvia ;

Akerley, Wallace ;

Scagliotti, Giorgio V. .

ONCOLOGIST, 2019, 24 (06) :E251-E259

[8]

Cancer Genome Atlas Research Network, 2018, Nature, V559, pE12, DOI [10.1038/nature13385, 10.1038/s41586-018-0228-6]

[9] Efficacy of First-line Chemotherapy Affects the Second-Line Setting Response in Patients with Advanced Non-Small Cell Lung Cancer [J].

Cao, Wa ;

Li, Ai-Wu ;

Ren, Sheng-Xiang ;

Chen, Xiao-Xia ;

Li, Wei ;

Gao, Guang-Hui ;

He, Ya-Yi ;

Zhou, Cai-Cun .

ASIAN PACIFIC JOURNAL OF CANCER PREVENTION, 2014, 15 (16) :6799-6804

[10] Gefitinib or erlotinib in previously treated non-small-cell lung cancer patients: a cohort study in Taiwan [J].

Chang, Chia-Hao ;

Lee, Chih-Hsin ;

Ko, Jen-Chung ;

Chang, Lih-Yu ;

Lee, Ming-Chia ;

Wang, Jann-Yuan ;

Yu, Chong-Jen .

CANCER MEDICINE, 2017, 6 (07) :1563-1572

← 1 2 3 4 5 6 7 8 9 10 →